Journal of Clinical Oncology, Vol 6, 239-252, Copyright © 1988 by American Society of Clinical Oncology

ARTICLES

Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors

P Carde, JM Burgers, M Henry-Amar, M Hayat, W Sizoo, E Van der Schueren, M Monconduit, EM Noordijk, J Lustman-Marechal and A Tanguy
European Organization for the Research and Treatment of Cancer, Institut Gustave-Roussy, Villejuif, France.

The H5 program in clinical stage (CS) I to II supradiaphragmatic Hodgkin's disease (HD) was tailored to prognostic factors identified in former European Organization for the Research and Treatment of Cancer (EORTC) studies. Among the 494 adult patients included in the study, the 237 patients belonging to the favorable group (H5F) underwent a staging laparotomy (Sx) in order to select the patients who could be treated with limited radiotherapy (RT) only. Thus, 198 patients (84%) with negative laparotomy were treated with RT alone and randomized to either mantle irradiation (M) or extended field mantle plus para-aortic (M + PA) irradiation. Complete remission (CR) was achieved in 99% of the patients. There was no difference in the 6-year relapse-free survival (RFS) rate (74% and 72%, respectively) or survival rate (96% and 89%). Therefore, Sx helped to define those patients who could be treated with M alone in contrast to those who required more aggressive therapy. The 39 patients with positive laparotomy were treated as the unfavorable group (H5U) from onset and randomized to either total/subtotal nodal irradiation (TNI/STNI) or a sandwiched mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) X 3, M irradiation, MOPP X 3 protocol (3M). Although the RFS rate was higher in the 3M arm (100% v 53%; P = .002), the 6-year survival was not significantly different between the two arms (overall, 92%). In the 257 patients with initial unfavorable disease, the Sx was avoided. They were randomized to either TNI/STNI or 3M. In complete responders (96%), the 6-year RFS was 91% in the 3M arm and 77% in the TNI/STNI arm (P = .02). The pattern of failure differed in the two arms: the inverted Y and spleen irradiation controlled occult infradiaphragmatic disease better than MOPP; conversely, less patients begun on MOPP recurred in the involved mantle areas. The difference in 6-year actuarial total survival (TS) (89% and 82%; P = .05 in favor of the 3M arm) was not retrieved after exclusion of the unrelated deaths from the analysis. The two arms produced similar TS in patients under 40 years of age. TNI retains interest, especially in young men wishing to preserve fertility. The overall result shows that when treatment is tailored to initial prognostic factors, excellent results can be obtained in all patient subgroups at minimal morbidity and toxic cost.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Engert, J. Franklin, H. T. Eich, C. Brillant, S. Sehlen, C. Cartoni, R. Herrmann, M. Pfreundschuh, M. Sieber, H. Tesch, et al. Two Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Extended-Field Radiotherapy Is Superior to Radiotherapy Alone in Early Favorable Hodgkin's Lymphoma: Final Results of the GHSG HD7 Trial J. Clin. Oncol., August 10, 2007; 25(23): 3495 - 3502. [Abstract] [Full Text] [PDF]

				O. Landgren, U. Axdorph, T. R. Fears, A. Porwit-MacDonald, C. Wedelin, and M. Bjorkholm A population-based cohort study on early-stage Hodgkin lymphoma treated with radiotherapy alone: with special reference to older patients Ann. Onc., August 1, 2006; 17(8): 1290 - 1295. [Abstract] [Full Text] [PDF]

				E. M. Noordijk, P. Carde, N. Dupouy, A. Hagenbeek, A. D.G. Krol, J. C. Kluin-Nelemans, U. Tirelli, M. Monconduit, J. Thomas, H. Eghbali, et al. Combined-Modality Therapy for Clinical Stage I or II Hodgkin's Lymphoma: Long-Term Results of the European Organisation for Research and Treatment of Cancer H7 Randomized Controlled Trials J. Clin. Oncol., July 1, 2006; 24(19): 3128 - 3135. [Abstract] [Full Text] [PDF]

				J. M. Connors State-of-the-Art Therapeutics: Hodgkin's Lymphoma J. Clin. Oncol., September 10, 2005; 23(26): 6400 - 6408. [Abstract] [Full Text] [PDF]

				G. Bonadonna, V. Bonfante, S. Viviani, A. Di Russo, F. Villani, and P. Valagussa ABVD Plus Subtotal Nodal Versus Involved-Field Radiotherapy in Early-Stage Hodgkin's Disease: Long-Term Results J. Clin. Oncol., July 15, 2004; 22(14): 2835 - 2841. [Abstract] [Full Text] [PDF]

				A. Engert, P. Schiller, A. Josting, R. Herrmann, P. Koch, M. Sieber, F. Boissevain, M. de Wit, J. Mezger, E. Duhmke, et al. Involved-Field Radiotherapy Is Equally Effective and Less Toxic Compared With Extended-Field Radiotherapy After Four Cycles of Chemotherapy in Patients With Early-Stage Unfavorable Hodgkin's Lymphoma: Results of the HD8 Trial of the German Hodgkin's Lymphoma Study Group J. Clin. Oncol., October 1, 2003; 21(19): 3601 - 3608. [Abstract] [Full Text] [PDF]

				A. K. Ng, M. P. Bernardo, E. Weller, K. H. Backstrand, B. Silver, K. C. Marcus, N. J. Tarbell, J. Friedberg, G. P. Canellos, and P. M. Mauch Long-Term Survival and Competing Causes of Death in Patients With Early-Stage Hodgkin's Disease Treated at Age 50 or Younger J. Clin. Oncol., April 15, 2002; 20(8): 2101 - 2108. [Abstract] [Full Text] [PDF]

				O. W. Press, M. LeBlanc, A. S. Lichter, T. M. Grogan, J. M. Unger, T. H. Wasserman, E. R. Gaynor, B. A. Peterson, T. P. Miller, and R. I. Fisher Phase III Randomized Intergroup Trial of Subtotal Lymphoid Irradiation Versus Doxorubicin, Vinblastine, and Subtotal Lymphoid Irradiation for Stage IA to IIA Hodgkin's Disease J. Clin. Oncol., November 15, 2001; 19(22): 4238 - 4244. [Abstract] [Full Text]

				K. H. Backstrand, A. K. Ng, R. W. Takvorian, E. L. Jones, D. C. Fisher, B. J. Molnar-Griffin, B. Silver, N. J. Tarbell, and P. M. Mauch Results of a Prospective Trial of Mantle Irradiation Alone for Selected Patients With Early-Stage Hodgkin's Disease J. Clin. Oncol., February 1, 2001; 19(3): 736 - 741. [Abstract] [Full Text] [PDF]

				J. M. Connors, E. M. Noordijk, and S. J. Horning Hodgkin's Lymphoma: Basing the Treatment on the Evidence Hematology, January 1, 2001; 2001(1): 178 - 193. [Abstract] [Full Text] [PDF]

				A. Guermazi, P. Brice, E. de Kerviler, C. Ferme, C. Hennequin, V. Meignin, and J. Frija Extranodal Hodgkin Disease: Spectrum of Disease RadioGraphics, January 1, 2001; 21(1): 161 - 179. [Abstract] [Full Text] [PDF]

				F. E. van Leeuwen, W. J. Klokman, M. B. v.’t Veer, A. Hagenbeek, A. D. G. Krol, U. A. O. Vetter, M. Schaapveld, P. van Heerde, J. M. V. Burgers, R. Somers, et al. Long-Term Risk of Second Malignancy in Survivors of Hodgkin’s Disease Treated During Adolescence or Young Adulthood J. Clin. Oncol., February 1, 2000; 18(3): 487 - 487. [Abstract] [Full Text] [PDF]

				A. K. Ng, J. C. Weeks, P. M. Mauch, and K. M. Kuntz Laparotomy Versus No Laparotomy in the Management of Early-Stage, Favorable-Prognosis Hodgkin's Disease: A Decision Analysis J. Clin. Oncol., January 1, 1999; 17(1): 241 - 241. [Abstract] [Full Text] [PDF]

				P. Brice Prognostic Factors in Advanced Hodgkin's Disease -- Can They Guide Therapeutic Decisions? N. Engl. J. Med., November 19, 1998; 339(21): 1547 - 1549. [Full Text]

				P. S. Multani and M. L. Grossbard Staging Laparotomy in the Management of Hodgkin's Disease: Is it Still Necessary? Oncologist, February 1, 1996; 1(1): 41 - 55. [Abstract] [Full Text] [PDF]

				P. M. Mauch and J. A. Ferry Case 19-1993- A 39-Year-Old Man with Bilateral Renal Masses a Few Months after Treatment for Hodgkin's Disease, Stage IIA N. Engl. J. Med., May 13, 1993; 328(19): 1406 - 1414. [Full Text]

				M. Henry-Amar, S. Friedman, M. Hayat, R. Somers, J. H. Meerwaldt, P. Carde, J. M. V. Burgers, J. Thomas, M. Monconduit, E. M. Noordijk, et al. Erythrocyte Sedimentation Rate Predicts Early Relapse and Survival in Early-Stage Hodgkin Disease Ann Intern Med, March 1, 1991; 114(5): 361 - 365. [Abstract] [PDF]